Research Evidence / Overview of Studies for Nupenta-DSR
The clinical evaluation for this medicine, which combines Pantoprazole and Domperidone, often studied under the name Nupenta-DSR, focuses on official studies that examine its research profile in specific digestive conditions. This overview draws only from the body of evidence provided by clinical trials and regulatory summaries, focusing on the types of research conducted and what remains uncertain.
Evidence for Use in Gastroesophageal Reflux Disease (GERD) with Concurrent Motility Symptoms
Research exploring this medicine has primarily focused on adults diagnosed with Gastroesophageal Reflux Disease (GERD), particularly when the condition is accompanied by symptoms related to slowed movement of the digestive tract. The main types of research conducted were short-term Randomized Controlled Trials (RCTs) and scientific reviews that combined data from multiple trials.
These studies were used in research exploring how symptoms change over time, and they monitored patient-reported outcomes describing perceived discomfort. Researchers mainly examined how symptoms like heartburn and regurgitation evolved during the study period. In studies focusing on episodes where symptoms become more noticeable, research monitored patterns where comparisons between the medicine and Pantoprazole alone yielded differing measurements in overall symptom scores, especially in populations that presented with prominent motility issues. However, the evidence is limited, and studies report mixed findings regarding the medicine’s impact on endoscopic healing rates.
Evidence for Non-Ulcer Dyspepsia (NUD) and Related Functional Symptoms
Research explored this medicine in the context of conditions characterized by fluctuating or episodic manifestations, such as Gastritis and Non-Ulcer Dyspepsia (NUD), which often involve upper abdominal symptoms. These research scenarios primarily involved clinical trials and observational settings evaluating daily-life functioning.
Studies explored the medicine's use during periods of increased symptom activity and monitored patient-reported outcomes describing perceived discomfort related to bloating, fullness, and pain. The evidence base for these specific conditions is more limited, drawing from a mixture of trial types. Studies report how symptoms evolved in the observed populations, and findings indicate patterns related to the monitored outcomes over short-term observation intervals, often four weeks or less.
Long-Term Studies and Follow-Up Durations
The follow-up durations for most of the primary studies that provided data to regulators were limited. The main research was designed to assess short-term or episodic symptom patterns and monitored symptom evolution over defined time intervals, usually four to eight weeks.
Consequently, limited information is available for long-term outcomes. The research base does not offer detailed insight into the long-term status of symptoms after the short-term observation period. Long-term effects are not fully established, and research focusing on maintenance of relief over extended time remains limited.
Evidence in Specific Populations
Research was primarily applied in studies examining patient-reported experiences in the general adult population. The medicine was observed in specific subgroups, such as adults whose GERD symptoms were not fully resolved by initial monotherapy, which is sometimes described as PPI-refractory GERD.
However, data for certain groups remain insufficient. For instance, the research base provides limited data for children, older adults, or patients with complex comorbid conditions. As a result, the findings apply mainly to the populations studied in the RCTs, and comparative evidence is lacking or subgroup findings are not fully characterized for these special populations.
Key Limitations and Areas of Research Uncertainty
The existing research provides insight into short-term changes, but several limitations restrict the certainty of broad conclusions. A key limitation is that follow-up durations were limited, meaning the evidence contributes to understanding symptom patterns over defined, short-term periods only.
Evidence quality varies across studies, and some trials used sample sizes that were modest. Moreover, findings were mixed across different studies, particularly when comparing the medicine directly to Pantoprazole monotherapy in terms of incremental benefit for all measured outcomes. Comparative evidence is lacking for many patient subgroups. Therefore, research provides context but not individual predictions, and findings describe group patterns while highlighting what is known—and what is still uncertain—about this medicine.
Key Studies & References
- Efficacy and safety of domperidone in combination with proton pump inhibitors in gastroesophageal reflux disease: a systematic review and meta-analysis of randomised controlled trials
- Ethiopian Food and Drug Authority (EFDA) - Product Monograph for Pantoprazole/Domperidone Combination
